United States

Cipla Ltd (CIPL.BO)

CIPL.BO on Bombay Stock Exchange

21 Oct 2016
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Cipla Ltd announces an investment led by Fidelity Growth Partners India into the newly launched Consumer Healthcare business
Tuesday, 21 Jul 2015 09:32am EDT 

Cipla Ltd:Says has approved investmen by Fidelity Growth Partners India and US based Fidelity Biosciences, through FIL Capital Investments II Ltd or its affiliates in its recently launched consumer healthcare business which is under incorporation.  Full Article

Cipla Ltd and Bristol-Myers Squibb settles patent dispute - Business Standard
Tuesday, 16 Jun 2015 08:00pm EDT 

Cipla Ltd:Says patent dispute between Bristol-Myers Squibb (BMS) and Cipla over entecavir, a pharmaceutical combination for treating Hepatitis B has been settled amicably out of the court - Business Standard.Says Counsels appearing for both the parties informed the Appellate Board that the matter has been settled out of court in April, 2015.Says taking the endorsement to the registry on record, the bench comprising of IPAB Chairman Justice K N Basha and Technical Member (Patent) DPS Parmar dismissed the application as withdrawn not pressed.Says companies requested the terms of settlement has to be kept confidential.  Full Article

Cipla Ltd receives Japan process patent for its novel stem cell drug 'Stempeucel'
Monday, 8 Jun 2015 02:41am EDT 

Cipla Ltd:Announces that it has been granted process patent from the Japan Patent Office (application no 2012-540529) for its novel stem-cell based drug Stempeucel.Says the novelty covers the method of preparing master cell banks, working cell banks and the final therapeutic product 'Stempeucel' based on the novel pooling technology.  Full Article

Cipla Ltd says U.S. FDA approves AIDS treatment in infants and young children
Wednesday, 3 Jun 2015 06:17am EDT 

Cipla Ltd:Says U.S. FDA approval for paediatric lopinavir and ritonavir oral pellets for treatment of aids in infants and young children.Received US FDA approval for an innovative formulation — Lopinavir/ ritonavir (LPV/r) 40mg/ 10 mg oral pellets — for paediatric specific treatment for infants.  Full Article

Cipla Ltd says JV Partner gets orphan drug status in EU for stem cell drug
Monday, 1 Jun 2015 05:53am EDT 

Cipla Ltd:Says Stempeutics receives orphan drug designation in the European union for its novel stem cell drug stempeucel.  Full Article

Cipla Ltd board recommends dividend
Friday, 29 May 2015 08:55am EDT 

Cipla Ltd:Recommended payment of dividend of 2 Indian rupees per equity share (face value 2 Indian rupees per equity share) for the year 2014-1.Dividend, subject to the approval of shareholders, will be dispatched / credited on or after Sept. 01.  Full Article

Cipla Ltd's Cipla EU to acquire Duomed Produtos-Business Standard
Thursday, 9 Apr 2015 02:12am EDT 

Cipla Ltd:Said its UK subsidiary Cipla EU Ltd will acquire Brazilian firm Duomed Produtos Farmaceuticos for about 26 mln Indian Rupees-Business Standard.The deal has the approval of Brazilian health authority (ANVISA) and other regulatory authorities to import and distribute pharmaceutical products in Brazil, the filing said.The transaction is expected to be completed by end of May 2015.  Full Article

Cipla Ltd's Cipla (EU) Ltd to form JVC with Biopharm SPA-Business Standard
Friday, 13 Feb 2015 01:45am EST 

Cipla Ltd:Entered into an agreement with Biopharm SPA to form a joint venture company (JVC) in Algeria to manufacture and market respiratory products-Business Standard.Cipla (EU) Ltd, will hold a 40 per cent stake in the JV company while the remainder will be held by a Biopharm-led Algerian consortium.  Full Article

Cipla Ltd wins 188.95 million of Global Fund ARV Tender
Friday, 13 Feb 2015 12:05am EST 

Cipla Ltd:Announces that it has been awarded $188.95 million of Global Fund ARV Tender.Says that it has been selected as a ‘Panel Supplier’ for a supplier partnership agreement.Says the the contract is effective from Jan. 1 and will run for a period of three years.Says the supplies will begin from Q4 FY 2015.  Full Article

Cipla Ltd signs definitive agreement to acquire 60 pct stake of Jay Precision Pharmaceuticals Private Limited
Thursday, 12 Feb 2015 08:30am EST 

Cipla Ltd:Signs a definitive agreement to acquire 60 pct stake of Jay Precision Pharmaceuticals Private Limited, Mumbai, from the existing shareholders, for a cash consideration of 960 mln Indian Rupees.Jay Precision is an existing supplier of respiratory devices to Company and has a state of the art manufacturing facility at Vasai, Maharashtra.Considering Company's position in inhalation therapy, this transaction is aimed at integrating the value chain and will serve as platform for development of next generation respiratory devices.Pharmaceutical undertaking of Jay Precision Products (India) Private Limited was demerged into Jay Precision effective Jan. 01, 2014.Transaction is expected to be completed by end of this financial year, subject to completion of certain conditions.  Full Article

BRIEF-Cipla gets EIR from USFDA for its Indore facility

* Cipla receives EIR from the US FDA for its Indore facility Source text: http://bit.ly/2e8Sy2g Further company coverage: (Bengaluru newsroom)